VirtualScopics (NASDAQ: VSCP) 50.8% HIGHER; reported Q3 EPS of ($0.02), versus ($0.33) reported last year. Revenue for the quarter came ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Compass Point Cuts Price Target on KeyCorp (KEY) Following Announced First Niagara (FNFG) Acquisition November 3, 2015 9:44 AM Margin Pressures Could Weigh on CVS Health (CVS) Shares; Oppenheimer Cuts Price Target to $115 November 2, 2015 11:16 AM UBS Cuts Price Target on KeyCorp (KEY) Ahead of FNFG Deal November 2, 2015 11:07 AM Genworth Financial (GNW) Hires New President to Focus on Life Operations; Compass Point Reiterates Buy November 2, 2015 8:29 AM Leerink Partners Would Buy CVS Health (CVS) on Current Weakness October 30, 2015 1:39 PM Valeant Pharmaceuticals (VRX) Bull-Bear Debate RagesOctober 30, 2015 12:57 PM Valeant Pharma (VRX) falls below $100 againOctober 30, 2015 11:58 AM Needham & Company Reiterates Buy Following ON Semiconductor's (ON) 3Q October 30, 2015 11:58 AM Bill Ackman said their average cost on Valeant Pharma (VRX) is $186October 30, 2015 11:11 AM UPDATE: VirtualScopics (VSCP) Taps Session HighOctober 30, 2015 11:00 AM Cowen Cuts Price Target on SolarCity (SCTY) Following 3Q EPS Miss October 30, 2015 10:34 AM Growth Drivers Set For LinkedIn's (LNKD) 2016; SunTrust Robinson Humphrey Raises Price Target to $280 October 30, 2015 10:21 AM Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-TermOctober 30, 2015 10:14 AM Evercore ISI Reiterates Hold Following Expedia's (EXPE) 3Q October 30, 2015 10:13 AM Evercore ISI Raises Price target on LinkedIn (LNKD) to $235 Following 3Q October 30, 2015 10:05 AM RBC Capital Raises Price Target on Expedia (EXPE) Following 3Q Earnings Results October 30, 2015 9:57 AM Needham & Company Raises Price Target on Cray (CRAY) to $35 Following a 42c EPS Beat October 30, 2015 9:42 AM